Hims House Ep 42 - Shaun Noorian, CEO of Empower Pharmacy, on GLP-1s, Patents, and the Future of Compounding
21 snips
Aug 19, 2025 
Shaun Noorian, the founder and CEO of Empower Pharmacy, leads the world's largest compounding pharmacy, advocating for personalized medicine. He dives into the misconceptions about GLP-1 drugs and the ongoing legal battle against Eli Lilly over tirzepatide patents. The discussion highlights the critical role compounding plays in healthcare, not as a loophole but as a necessary service. Noorian also outlines future trends in hormone therapy and peptides, navigating the complexities of regulations and patient safety in an evolving industry.
AI Snips
Chapters
Transcript
Episode notes
Scale Meets Personalized Medicine
- Empower built vertically integrated 503A and 503B facilities to scale personalized medicine with pharma-level rigor.
- Shaun Noorian argues this model restores patient-provider relationships and improves outcomes.
Why GLP-1 Rumors Mislead
- Many rumors of 503Bs restarting GLP-1 production are actually 503As resuming orders or 503Bs disguising operations.
- Noorian says 503Bs legally cannot make GLP-1s outside a declared shortage and would be shut down if they tried.
Verify Supplier Type Before Ordering
- Verify whether a supplier is a 503A or 503B before sending patient prescriptions or names.
- Rely on licensed compounding channels, because some vendors market availability while actually routing through 503As.